Expression of Eotaxin, an Eosinophil-selective Chemokine, Parallels Eosinophil Accumulation in the Vesiculobullous Stage of Incontinentia Pigmenti

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2002 Apr 23

PMID 11966763

Citations 12

Authors

S Jean-Baptiste

E A OToole

M Chen

J Guitart

A Paller

L S Chan

Affiliations

Soon will be listed here.

Abstract

Incontinentia pigmenti (IP) is an X-linked dominant genodermatosis primarily affecting female children. The initial vesiculobullous stage of IP is characterized clinically by inflammatory papules, blisters, and pustules, and histopathologically by acanthosis, keratinocyte necrosis, epidermal spongiosis and massive epidermal eosinophil infiltration. The cause of this multisystem disease is attributed to the mutations of an X-linked regulatory gene, termed nuclear factor-kappaB essential modulator (NEMO). The exact mechanism of epidermal eosinophil accumulation has not yet been determined. We explored the possible role of an eosinophil-selective, nuclear factor-kappaB-activated chemokine, eotaxin, in the accumulation of eosinophils in the initial stage of the disease. Monoclonal antibody (6H9) specific for human eotaxin strongly labelled the suprabasal epidermis of IP skin, paralleling the upper epidermal accumulation of eosinophils, but did not label the epidermis of normal skin or lesional skin from patients with other inflammatory skin diseases not characterized by prominent eosinophil accumulation, namely dermatitis herpetiformis and selected cases of atopic dermatitis lacking significant numbers of eosinophils. In addition, endothelial cells in lesional skin of IP also exhibited strong expression of eotaxin, which correlated with perivascular and intravascular eosinophil infiltration. We also examined the in vitro effects on epidermally derived eotaxin of several cytokines that were nuclear factor-kappaB-activated and/or known to induce eotaxin expression. In normal human keratinocytes, proinflammatory cytokines either independently (IL-1alpha) or synergistically (tumour necrosis factor-alpha (TNF-alpha)/ interferon-gamma (IFN-gamma) and TNF-alpha/IL-4) up-regulated eotaxin expression. These studies suggest that release of cytokines during the initial inflammatory stage of IP induces epidermal expression of eotaxin, which may play a role in the epidermal accumulation of eosinophils.

Citing Articles

Case Report: Diagnosis and treatment of with central nervous system anomalies in one patient.

Li Y, Hong J, Xu S, Zhou T, Xiao X, Yang J Front Pediatr. 2025; 12:1490816.

PMID: 39882206 PMC: 11774900. DOI: 10.3389/fped.2024.1490816.

Partial Loss of NEMO Function in a Female Carrier with No Incontinentia Pigmenti.

Cifaldi C, Sgrulletti M, Cesare S, Rivalta B, Emanuele A, Colucci L J Clin Med. 2025; 14(2.

PMID: 39860371 PMC: 11765721. DOI: 10.3390/jcm14020363.

Uncovering incontinentia pigmenti: From DNA sequence to pathophysiology.

How K, Leong H, Pramono Z, Leong K, Lai Z, Yap W Front Pediatr. 2022; 10:900606.

PMID: 36147820 PMC: 9485571. DOI: 10.3389/fped.2022.900606.

Regulation of eotaxin expression in skin allergic diseases.

Peng C, Zhang H, Yang J, Xu J, Guan S, Xia J Postepy Dermatol Alergol. 2022; 39(3):565-579.

PMID: 35950112 PMC: 9326924. DOI: 10.5114/ada.2022.117739.

Eosinophils in skin diseases.

Radonjic-Hoesli S, Bruggen M, Feldmeyer L, Simon H, Simon D Semin Immunopathol. 2021; 43(3):393-409.

PMID: 34097126 PMC: 8241748. DOI: 10.1007/s00281-021-00868-7.

References

Gorski J, Burright E . The molecular genetics of incontinentia pigmenti. Semin Dermatol. 1993; 12(3):255-65. View

Landy S, Donnai D . Incontinentia pigmenti (Bloch-Sulzberger syndrome). J Med Genet. 1993; 30(1):53-9. PMC: 1016235. DOI: 10.1136/jmg.30.1.53. View

Ganzalo J, Jia G, Aguirre V, Friend D, Coyle A, Jenkins N . Mouse Eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response. Immunity. 1996; 4(1):1-14. DOI: 10.1016/s1074-7613(00)80293-9. View

Garcia-Zepeda E, Rothenberg M, Ownbey R, Celestin J, Leder P, Luster A . Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996; 2(4):449-56. DOI: 10.1038/nm0496-449. View

Ponath P, Qin S, Ringler D, Clark-Lewis I, Wang J, Kassam N . Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996; 97(3):604-12. PMC: 507095. DOI: 10.1172/JCI118456. View

Bartels J, Schluter C, Richter E, Noso N, Kulke R, Christophers E . Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression, and identification of eotaxin sequence variants. Biochem Biophys Res Commun. 1996; 225(3):1045-51. DOI: 10.1006/bbrc.1996.1292. View

Bickel M, Nothen S, Freiburghaus K, Shire D . Chemokine expression in human oral keratinocyte cell lines and keratinized mucosa. J Dent Res. 1996; 75(11):1827-34. DOI: 10.1177/00220345960750110301. View

Rothenberg M, MacLean J, Pearlman E, Luster A, Leder P . Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med. 1997; 185(4):785-90. PMC: 2196140. DOI: 10.1084/jem.185.4.785. View

Barnes P, Karin M . Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336(15):1066-71. DOI: 10.1056/NEJM199704103361506. View

10.

Lilly C, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda E . Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest. 1997; 99(7):1767-73. PMC: 507998. DOI: 10.1172/JCI119341. View

11.

Francis J, Sybert V . Incontinentia pigmenti. Semin Cutan Med Surg. 1997; 16(1):54-60. DOI: 10.1016/s1085-5629(97)80036-3. View

12.

Chen M, Marinkovich M, Veis A, Cai X, Rao C, OToole E . Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal-dermal adherence in human skin. J Biol Chem. 1997; 272(23):14516-22. DOI: 10.1074/jbc.272.23.14516. View

13.

OToole E, Marinkovich M, Hoeffler W, Furthmayr H, Woodley D . Laminin-5 inhibits human keratinocyte migration. Exp Cell Res. 1997; 233(2):330-9. DOI: 10.1006/excr.1997.3586. View

14.

Ghosh S, May M, Kopp E . NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998; 16:225-60. DOI: 10.1146/annurev.immunol.16.1.225. View

15.

Li L, Xia Y, Nguyen A, Lai Y, Feng L, Mosmann T . Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol. 1999; 162(5):2477-87. View

16.

Yawalkar N, Uguccioni M, Scharer J, Braunwalder J, Karlen S, DEWALD B . Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol. 1999; 113(1):43-8. DOI: 10.1046/j.1523-1747.1999.00619.x. View

17.

Rothenberg M . Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol. 1999; 21(3):291-5. DOI: 10.1165/ajrcmb.21.3.f160. View

18.

OToole E, Mak L, Guitart J, Woodley D, Hashimoto T, Amagai M . Induction of keratinocyte IL-8 expression and secretion by IgG autoantibodies as a novel mechanism of epidermal neutrophil recruitment in a pemphigus variant. Clin Exp Immunol. 1999; 119(1):217-24. PMC: 1905536. DOI: 10.1046/j.1365-2249.2000.01104.x. View

19.

Kampen G, Stafford S, Adachi T, Jinquan T, Quan S, Grant J . Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood. 2000; 95(6):1911-7. View

20.

van Leeuwen R, Wintzen M, van Praag M . Incontinentia pigmenti: an extensive second episode of a "first-stage" vesicobullous eruption. Pediatr Dermatol. 2000; 17(1):70. DOI: 10.1046/j.1525-1470.2000.017001070.x. View